StockNews.com assumed coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP – Get Rating) in a research note published on Saturday. The brokerage issued a sell rating on the stock. Separately, Alliance Global Partners restated a buy rating and set a $6.50 price objective on shares of Tonix Pharmaceuticals in a report on Thursday, January 12th. Tonix […]